1-4 of 4
Helene Caillon, PharmD
Close
Sort by
Journal Articles

Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma

Mauricette Michallet, MD PhD, Colette Chapuis-Cellier, Dr, Christine Lombard, Dr, Mohamad Sobh, PharmD, Thomas Dejoie, PharmD, Helene Caillon, PharmD, Michel Attal, Philippe Moreau, Herve Avet-Loiseau, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3245.
https://doi.org/10.1182/blood.V128.22.3245.3245
Published: 2016
Journal Articles

Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab

Helene Caillon, PharmD, Alix Irimia, Residential student, Jason S. Simon, PhD, Amy Axel, Kate Sasser, Matthew James Scullion, PhD BSc, Thierry Ligneel, PhD, Georges Nouadje, PhD, Philippe Moreau, Thomas Dejoie, PharmD
Journal: Blood
Blood (2016) 128 (22): 2063.
https://doi.org/10.1182/blood.V128.22.2063.2063
Published: 2016
Journal Articles

Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon

Helene Caillon, PharmD, Michel Attal, Herve Avet-Loiseau, MD PhD, Cyrille Touzeau, MD, Philippe Moreau, Thomas Dejoie, PharmD
Journal: Blood
Blood (2016) 128 (22): 4428.
https://doi.org/10.1182/blood.V128.22.4428.4428
Published: 2016
Journal Articles

Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial

Jill Corre, PharmD, PhD, Thomas Dejoie, PharmD, Helene Caillon, PharmD, Michel Attal, MD, Herve Avet-Loiseau, Philippe Moreau, MD
Journal: Blood
Blood (2014) 124 (21): 180.
https://doi.org/10.1182/blood.V124.21.180.180
Published: 2014